In addition, in NSCLC, a number of other RTK pathways such as EGFR, ALK, and ROS1 (upon ligand binding or mutations) can also crosstalk and dynamically interact with the MET pathway to collectively regulate cell growth and survival and thus contribute to tumorigenesis (Remon et al., 2021; Fu et al., 2022; Korpanty et al., 2014; D, 2024). Here, EGFR is linked to non-small cell lung carcinoma.